Skip to main content
SpringerLink
Log in

Monitoring Efficacy of Treatment with Brain Natriuretic Peptide

  • Chapter
Cardiac Markers

Part of the book series: Pathology and Laboratory Medicine ((PLM))

  • 175 Accesses

Abstract

Congestive heart failure (CHF) is a major health problem. Its incidence and prevalence are increasing because of the aging of the population and improved treatment and outcomes (1). Hospital admissions for CHF increased dramatically from 377,000 in 1979 to 970,000 in 1998 according to the National Hospital Discharge Survey (2). Despite advances in treatment, mortality from CHF remains high, especially in patients with more advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Miller L, Missov E. Epidemiology of heart failure. Cardiol Clin 2001; 19: 547–555.

    Article  PubMed  CAS  Google Scholar 

  2. Haldeman G, Croft J, Giles W, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352–360.

    Article  PubMed  CAS  Google Scholar 

  3. Espiner E. Physiology of natriuretic peptides. J Intern Med 1994; 235: 527–541.

    Article  PubMed  CAS  Google Scholar 

  4. Mair J, Friedl W, Thomas S, et al. Natriuretic peptides in assessment of left ventricular dysfunction.scand J Clin Lab Invest 1999; 59: 132–142.

    CAS  Google Scholar 

  5. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 2001; 19: 557–571.

    Article  PubMed  CAS  Google Scholar 

  6. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for b-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Cardiac Fail 2001; 7: 21–29.

    Article  CAS  Google Scholar 

  7. Sasaki T, Kubo T, Komamura K, Nishikimi T. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardiol 1999; 33: 317–325.

    PubMed  CAS  Google Scholar 

  8. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am J Coll Cardiol 2001; 37: 379–385.

    Article  CAS  Google Scholar 

  9. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for b-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37: 386–391.

    Article  PubMed  CAS  Google Scholar 

  10. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized cornparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126–1132.

    Article  PubMed  CAS  Google Scholar 

  11. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–1130.

    Article  PubMed  CAS  Google Scholar 

  12. Stanek B, Frey B, Hülsmann, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436–442.

    Google Scholar 

  13. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 1999; 99: 786–792.

    Article  PubMed  CAS  Google Scholar 

  14. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001; 37: 1781–1787.

    Article  PubMed  CAS  Google Scholar 

  15. Kawai K, Hata K, Takaoka H, et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 2001; 141: 925–932.

    Article  PubMed  CAS  Google Scholar 

  16. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–1233.

    Article  PubMed  CAS  Google Scholar 

  17. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne’s muscular dystrophy. Am Heart J 1999; 137: 895–902.

    Article  PubMed  CAS  Google Scholar 

  18. Nousiainen T, Jantunen E, Vanninen E, et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol 1999; 62: 135–141.

    Article  PubMed  CAS  Google Scholar 

  19. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001; 19: 2746–2753.

    PubMed  CAS  Google Scholar 

  20. Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309–313.

    Article  PubMed  CAS  Google Scholar 

  21. Okumura H, Iuchi K, Yoshida T, et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158–163.

    Article  PubMed  CAS  Google Scholar 

  22. Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001; 37: 4–9.

    Article  PubMed  CAS  Google Scholar 

  23. Ohsaki Y, Gross AJ, Le PT, Oie H, Johnson BE. Human small cell lung cancer cells produce brain natriuretic peptide. Oncology 1999; 56: 155–159.

    Article  PubMed  CAS  Google Scholar 

  24. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39: 571–588.

    Article  PubMed  CAS  Google Scholar 

  25. Kato J, Kitamura K, Matsui E, et al. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res1999; 22: 61–65.

    Google Scholar 

  26. Minami J, Nishikimi T, Ishimitsu T, et al. Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension. J Cardiovasc Pharmacol 2000; 36 (Suppl 2): S83 — S86.

    Article  PubMed  CAS  Google Scholar 

  27. Nishikimi T, Matsuoka H, Ishikawa K, et al. Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. Hypertens Res 1996; 19: 97–101.

    Article  PubMed  CAS  Google Scholar 

  28. Ohta Y, Shimada T, Yoshitomi H, et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001; 17: 415–420.

    PubMed  CAS  Google Scholar 

  29. Horie H, Tsutamoto T, Ishimoto N, et al. Plasma brain natriuretic peptide as a biochemical marker for atrioventricular sequence in patients with pacemakers. Pacing Clin Electrophysiol 1999; 22: 282–290.

    Article  PubMed  CAS  Google Scholar 

  30. Master R, Davies R, Keon W, et al. Neuroendocrine response to cardiac transplantation. Can J Cardiol 1993; 9: 609–617.

    Google Scholar 

  31. El Gamel A, Yonan N, Keevil B, et al. Significance of raised natriuretic peptides after bica-val and standard cardiac transplantation. Ann Thorac Surg 1997; 63: 1095–1100.

    Article  PubMed  Google Scholar 

  32. Farge D, Perrier P, Viossat I, et al. Elevation of plasma natriuretic factor after cardiac transplantation in rats. Transplantation 1990; 50: 167–170.

    Article  PubMed  CAS  Google Scholar 

  33. Masters RG, Davies RA, Veinot JP, et al. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999; 100: 287–291.

    Article  PubMed  CAS  Google Scholar 

  34. Lisman K, Stetson S, Koerner M. Managing heart failure with immunomodulatory agents. Cardiol Clin 2001; 19: 547–555.

    Article  Google Scholar 

  35. Missov E, Wieczorek S, Wu A, et al. Brain natriuretic peptide levels are associated with improved clinical status in patients with chronic heart failure after treatment with Enbrel (etanerept, TNF receptor) (abstract). Circulation 2000; 102: 1I - 532.

    Google Scholar 

  36. Missov E, Boularan AM, Bonifacj C, et al. Prognostic value of myocardial lactate dehydrogenase subunit ratio in heart transplant recipients. J Heart Lung Transplant 1998; 17: 959–968.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Emil D. Missov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie W. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Hartford Hospital, Hartford, CT, USA

    Alan H. B. Wu PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Missov, E.D., Miller, L.W. (2003). Monitoring Efficacy of Treatment with Brain Natriuretic Peptide. In: Wu, A.H.B. (eds) Cardiac Markers. Pathology and Laboratory Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-385-9_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-385-9_25

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-319-0

  • Online ISBN: 978-1-59259-385-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation